Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

WT1-H/K-HELP-survivin-H/K-HELP-MAGE-A4-H ⁄ K-HELP-MUC1-22 peptide-loaded autologous dendritic cells

A preparation of autologous dendritic cells (DCs) pulsed with helper/killer-hybrid epitope long peptides (H/K-HELP) of Wilms tumor 1 (WT1 H/K-HELP), survivin, melanoma-associated antigen 4 (MAGE-4) and human mucin 1-22 (Muc1-22), with potential immunomodulating and antineoplastic activities. Upon administration of WT1-H/K-HELP-survivin-H/K-HELP-MAGE-A4-H ⁄ K-HELP-Muc1-22 peptide-loaded autologous DCs may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL), T-helper (Th), and antibody responses against WT1-, survivin-, MAGE-4- and Muc1-22-expressing cancer cells, resulting in tumor cell lysis. WT1, survivin, MAGE-4 and Muc-1-22, tumor-associated antigens (TAAs), are overexpressed on a variety of cancer cells. The DCs loaded with the long fusion polypeptides, comprising of one or more helper epitopes and killer epitopes, may enhance antigen-specific CTL and Th cell production more efficiently than when the DCs are loaded with a mixture of helper epitope and killer epitope.
Synonym:WT1-H/K-HELP-Survivin-H/K-HELP-MAGE-A4-H ⁄ K-HELP-MUC1-22 peptide-loaded autologous DCs
Search NCI's Drug Dictionary